Capula Management’s NeoGenomics NEO Stock Holding History

Capula Management’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,840	Closed	-$554K	–	669
2023 Q1	$554K	Buy	+31,840	New	+$454K	0.01%	402

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capula Management's NEO Position: Q2 2023 in Review

Capula Management sold out of NeoGenomics (NEO) in Q2 2023, closing a stake of 31,840 shares — an estimated $554K sold.

Capula Management first reported a position in NEO in Q1 2023 and held it in 1 quarter. The position peaked at $554K in Q1 2023. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2023.

Capula Management reported no remaining NeoGenomics position as of Q2 2023 after selling out during the quarter.
Capula Management sold 31,840 NeoGenomics shares in Q2 2023, an estimated $554K.
Capula Management first reported a position in NeoGenomics in Q1 2023 and held it in 1 quarter.
Capula Management's NeoGenomics position peaked at $554K in Q1 2023.
266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2023.

Based on Capula Management's 13F filing for Q2 2023, filed 14 Aug 2023.